Biomarin Pharmaceutical Inc. - Registered Shares

NASDAQ:BMRN   3:59:59 PM EDT
79.62
+0.52 (+0.66%)
Products

Biomarin Expands Vosoritide Clinical Program

Published: 11/09/2020 13:47 GMT
Biomarin Pharmaceutical Inc (BMRN) - Biomarin Expands Vosoritide Clinical Program.
Biomarin Pharmaceutical - Enrolls First Child in Phase 2 Study for Children With Achondroplasia at Risk of Life-threatening Foramen Magnum Compression.
Biomarin - Expanding Clinical Program for Vosoritide With Two New Phase 2 Studies.
Biomarin - First Study is Sponsored by Co to Investigate Safety of Vosoritide in Infants With Achondroplasia at Risk of Life-threatening Foramen Magnum Compression.
Biomarin - Second Study is Investigator-initiated Study to Investigate Vosoritide in Children With Selected Genetic Forms of Short Stature.